Hormonal
Gastric accommodation (proximal stomach relaxation) is a primary physiological mechanism for controlling meal volume and satiation, and its impairment contributes to functional dyspepsia and gastroesophageal reflux disease (GORD).
If you suffer from early fullness or bloating (functional dyspepsia), standard 'motility' drugs might not help because the issue may be your stomach's inability to relax and accommodate food (gastric accommodation). Therapies that target this relaxation, such as specific receptor agonists (e.g., buspirone, tandospirone, or acotiamide where available), may offer symptomatic relief by improving how your stomach stretches.
Gastric accommodation is a relaxation of the proximal stomach... which allows storage of the ingested meal... The drop in IGP is mediated by nitric oxide and contributes to gastric nutrient volume tolerance while the rise in IGP from nadir determines satiation.
Why this rating
Based on multiple human studies, barostat measurements, and pharmacological trials cited in the review.
Source
The stomach in health and disease
Richard H. Hunt et al. · Gut · 2015
DOI 10.1136/gutjnl-2014-307595
More from this paper
- Ghrelin is the primary gastric hormone responsible for stimulating appetite (orexigenic effect) by crossing the blood-brain barrier and signaling via vagal afferents, while leptin (primarily from adipose tissue, some from stomach) acts as an anorexigenic signal.Strong
- Obese individuals exhibit increased fasting gastric volume and delayed satiation, allowing them to consume significantly more calories before reaching maximum satiation compared to normal-weight individuals.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →